|

SG301 placebo Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Hangzhou Sumgen Biotech Co., Ltd.1

Indications

  • Relapsed/ Refractory Multiple Myeloma1
  • Cancer1

Other1 trial

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.